JP2014530875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530875A5 JP2014530875A5 JP2014537311A JP2014537311A JP2014530875A5 JP 2014530875 A5 JP2014530875 A5 JP 2014530875A5 JP 2014537311 A JP2014537311 A JP 2014537311A JP 2014537311 A JP2014537311 A JP 2014537311A JP 2014530875 A5 JP2014530875 A5 JP 2014530875A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fatty acid
- composition according
- drug
- acid diester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 109
- 229930195729 fatty acid Natural products 0.000 claims description 109
- 239000000194 fatty acid Substances 0.000 claims description 109
- 239000008194 pharmaceutical composition Substances 0.000 claims description 95
- -1 fatty acid diester Chemical class 0.000 claims description 94
- 229920001223 polyethylene glycol Polymers 0.000 claims description 94
- 229940079593 drug Drugs 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 27
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 239000000654 additive Substances 0.000 claims description 19
- 230000000996 additive effect Effects 0.000 claims description 17
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 17
- 229960002100 cefepime Drugs 0.000 claims description 17
- 229930186147 Cephalosporin Natural products 0.000 claims description 16
- 229940124587 cephalosporin Drugs 0.000 claims description 16
- 150000001780 cephalosporins Chemical class 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 14
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 12
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims description 8
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 6
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 6
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 125000000185 sucrose group Chemical group 0.000 claims description 5
- QXNSHVVNEOAAOF-RXMQYKEDSA-N (6R)-4-oxa-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound S1OC=CN2[C@H]1CC2=O QXNSHVVNEOAAOF-RXMQYKEDSA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 4
- 229960003644 aztreonam Drugs 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 claims description 4
- 229940036735 ceftaroline Drugs 0.000 claims description 4
- 229960004828 ceftaroline fosamil Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960002770 ertapenem Drugs 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000014666 liquid concentrate Nutrition 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 2
- 229960000895 doripenem Drugs 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 description 73
- 150000004665 fatty acids Chemical class 0.000 description 36
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical group C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 5
- 201000003984 candidiasis Diseases 0.000 description 5
- 206010007134 Candida infections Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 2
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 108010049047 Echinocandins Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 2
- 229960003866 cefaloridine Drugs 0.000 description 2
- XAKKNLNAJBNLPC-MAYKBZFQSA-N cefluprenam Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 description 2
- 229950001334 cefluprenam Drugs 0.000 description 2
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 2
- 229950004036 cefpimizole Drugs 0.000 description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 2
- 229960000466 cefpirome Drugs 0.000 description 2
- 229950009592 cefquinome Drugs 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 108010081349 aculeacin A Proteins 0.000 description 1
- FBCLKBXYZRAXNA-PDIPHZEPSA-N aculeacin A Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCCCCCC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 FBCLKBXYZRAXNA-PDIPHZEPSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010062092 echinocandin B Proteins 0.000 description 1
- FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549882P | 2011-10-21 | 2011-10-21 | |
| US61/549,882 | 2011-10-21 | ||
| PCT/US2012/061125 WO2013059664A1 (en) | 2011-10-21 | 2012-10-19 | Pharmaceutical compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018029249A Division JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530875A JP2014530875A (ja) | 2014-11-20 |
| JP2014530875A5 true JP2014530875A5 (enExample) | 2015-12-03 |
| JP6329486B2 JP6329486B2 (ja) | 2018-05-23 |
Family
ID=48141411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537311A Expired - Fee Related JP6329486B2 (ja) | 2011-10-21 | 2012-10-19 | 医薬組成物及びそれらの使用 |
| JP2018029249A Withdrawn JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018029249A Withdrawn JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9308263B2 (enExample) |
| EP (1) | EP2775831A4 (enExample) |
| JP (2) | JP6329486B2 (enExample) |
| IN (1) | IN2014CN03214A (enExample) |
| WO (1) | WO2013059664A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2775831A4 (en) * | 2011-10-21 | 2015-08-12 | Seachaid Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| EP2988751B1 (en) * | 2013-04-25 | 2019-02-20 | Seachaid Pharmaceuticals, Inc. | Oral cefepime compositions and uses thereof |
| JPWO2021006267A1 (enExample) * | 2019-07-08 | 2021-01-14 | ||
| CN111053755B (zh) * | 2019-12-31 | 2022-03-29 | 金日制药（中国）有限公司 | 一种高渗透性的头孢克肟胶囊制剂制备方法 |
| CN111450057A (zh) * | 2020-06-03 | 2020-07-28 | 江苏中牧倍康药业有限公司 | 一种硫酸头孢喹肟自微乳及其制备方法 |
| AU2021104067A4 (en) * | 2021-07-12 | 2021-09-09 | Pharmachem Australia Pty Ltd | Oral antibiotic formulation |
| EP4493164A1 (en) | 2022-03-17 | 2025-01-22 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising salts of salcaprozate and nicotinamide for improving oral bioavailability |
| EP4680206A1 (en) | 2023-03-17 | 2026-01-21 | Bristol-Myers Squibb Company | Pharmaceutical compositions for improving oral bioavailability |
| WO2024210196A1 (ja) * | 2023-04-06 | 2024-10-10 | Ｅａファーマ株式会社 | スルホンアミド誘導体を含有する自己乳化組成物および自己乳化製剤 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57146722A (en) * | 1981-03-06 | 1982-09-10 | Toyo Jozo Co Ltd | Pharmaceutical preparation having improved absorption |
| US4537772A (en) | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
| JPS61267528A (ja) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
| JP3440315B2 (ja) * | 1994-12-02 | 2003-08-25 | 小林製薬株式会社 | トイレ用洗浄剤組成物 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| WO2005004792A2 (en) | 2003-06-24 | 2005-01-20 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
| US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| EP1539117A4 (en) | 2002-06-28 | 2005-12-14 | Shire Lab Inc | FORMULATIONS BASED ON FENOFIBRATE AND / OR FENOFIBRATE DERIVATIVES HAVING IMPROVED ORAL BIOAVAILABILITY |
| US20050123602A1 (en) | 2003-09-25 | 2005-06-09 | Michaelis Arthur F. | Rifalazil formulations |
| US8329958B2 (en) | 2004-07-02 | 2012-12-11 | Biocon Limited | Combinatorial synthesis of PEG oligomer libraries |
| EP2974718A1 (en) * | 2005-04-29 | 2016-01-20 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| JP4343153B2 (ja) | 2005-05-12 | 2009-10-14 | 基博 中島 | 抗腫瘍組成物の製造方法 |
| US20080145411A1 (en) * | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
| KR20090086470A (ko) * | 2006-12-28 | 2009-08-12 | 레프로스 쎄라피우틱스 아이엔씨. | 앤티프로게스틴의 개선된 생물학적 이용가능성을 위한 방법들과 제형들 |
| US8362083B2 (en) * | 2008-01-15 | 2013-01-29 | C.B. Fleet Company Inc. | Taste-masked docusate compositions |
| EP2278997B1 (en) | 2008-04-21 | 2016-08-10 | Nanobio Corporation | Nanoemulsion influenza vaccine |
| US9241519B2 (en) | 2008-09-19 | 2016-01-26 | Ironclad Performance Wear Corporation | Glove for use in the oil and natural gas extraction industries |
| EP2338480A1 (en) * | 2009-12-22 | 2011-06-29 | LEK Pharmaceuticals d.d. | Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt |
| EP2775831A4 (en) * | 2011-10-21 | 2015-08-12 | Seachaid Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| EP2988751B1 (en) | 2013-04-25 | 2019-02-20 | Seachaid Pharmaceuticals, Inc. | Oral cefepime compositions and uses thereof |
-
2012
- 2012-10-19 EP EP12841549.4A patent/EP2775831A4/en not_active Withdrawn
- 2012-10-19 WO PCT/US2012/061125 patent/WO2013059664A1/en not_active Ceased
- 2012-10-19 JP JP2014537311A patent/JP6329486B2/ja not_active Expired - Fee Related
- 2012-10-19 US US14/352,966 patent/US9308263B2/en not_active Expired - Fee Related
- 2012-10-19 IN IN3214CHN2014 patent/IN2014CN03214A/en unknown
-
2018
- 2018-02-22 JP JP2018029249A patent/JP2018109037A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530875A5 (enExample) | ||
| JP6329486B2 (ja) | 医薬組成物及びそれらの使用 | |
| Rauseo et al. | Hope on the horizon: novel fungal treatments in development | |
| ES2274236T3 (es) | Complejos novedosos de esteres de acidos grasos de polihidroxialcanos y nacinamida. | |
| US20070231406A1 (en) | Use of gallium to treat biofilm-associated infections | |
| CN110279698B (zh) | 头孢特咯瓒抗生素组合物 | |
| ES2992403T3 (es) | Ceftolozano/tazobactam para el tratamiento de infecciones intrapulmonares | |
| US20080076749A1 (en) | Stabilizing compositions for antibiotics and methods of use | |
| JP6025712B2 (ja) | テトラサイクリン組成物 | |
| US20140274996A1 (en) | Tazobactam and ceftolozane antibiotic compositions | |
| US20100197650A1 (en) | Compositions and methods of treatment comprising ceftaroline | |
| CN113194943B (zh) | 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 | |
| EP3430400A1 (en) | Dosing regimens for treatment of fungal infections | |
| Spencer et al. | Systemic fungal infections: A pharmacist/researcher perspective | |
| ES2608046T3 (es) | Tratamiento de enfermedades asociadas al uso de antibióticos | |
| ES2428167T3 (es) | Composición farmacéutica bactericida activa anti-MRSA conteniendo carbapenemos | |
| Horcajada et al. | Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: What is in the pipeline? | |
| Singh et al. | Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics | |
| CN104203227A (zh) | 用于抑制或治疗多重耐药细菌的富里酸与抗生素组合物 | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| WO2017095265A1 (ru) | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения | |
| Zulfiqar et al. | Nanotechnology-Inspired Approaches for Improving the Stability of Cephradine Dry Suspension: The Role of Pharmaceutical Excipients | |
| Macesic et al. | Nystatin | |
| EA039541B1 (ru) | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения, способ ее получения и применение | |
| Cole et al. | Anti-infective innovations: highlights from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) |